Compare BioNano Genomics Inc (BNGO) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Xylem, Inc. — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Xylem, Inc. trades at $121.6 (market cap $28.89B). The key difference: Xylem, Inc. is far larger — about 2188.6× BioNano Genomics Inc's market cap, and Xylem, Inc. pays a 1.42% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | XYL | |
|---|---|---|
Market Cap | $13.20M | $28.89B |
Sector | Health | Industrials |
52-Week High | $4.92 | $152.95 |
52-Week Low | $1.09 | $106.34 |
Enterprise Value | $15.81M | $30.14B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
XYL trades at $121.21, showing minimal daily change. The stock maintains a bullish technical outlook with consistent earnings beats in recent quarters. Revenue grew to $9.04B in 2025 with a net margin of 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing growth in water technology solutions. Analyst consensus is mixed with a $153.14 price target suggesting 26% upside from current levels.
XYL offers solid fundamentals with expanding profitability and strong cash flow generation. Key risks include execution of growth initiatives and macroeconomic sensitivity. The stock presents a compelling opportunity for long-term investors seeking exposure to essential water infrastructure, though near-term volatility may persist around earnings announcements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
